Lineage Cell Therapeutics (LCTX) Revenue Growth (3y) (2013 - 2026)
Lineage Cell Therapeutics (LCTX) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,725.60 Bn | 68,725.31 Bn | - | - |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 472.73 Bn | 467.94 Bn | 1.35 Bn | 50.07% |
| 5 | Vertex Pharmaceuticals | 123.52 Bn | 116.27 Bn | 2.59 Bn | 7.94% |
| 6 | Regeneron Pharmaceuticals | 69.74 Bn | 60.99 Bn | 3.31 Bn | 4.47% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.42 Bn | 51.24 Bn | 1.41 Bn | 79.44% |
| 9 | Revolution Medicines | 37.76 Bn | 37.76 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 256.06 Mn | 193.34 Mn | 1.73 Mn | -10.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.25% |
| Dec 31, 2025 | 51.11% |
| Sep 30, 2025 | 7.08% |
| Jun 30, 2025 | -15.32% |
| Mar 31, 2025 | -34.05% |
| Dec 31, 2024 | -61.43% |
| Sep 30, 2024 | 18.52% |
| Jun 30, 2024 | 40.10% |
| Mar 31, 2024 | 54.57% |
| Dec 31, 2023 | 80.51% |
| Sep 30, 2023 | 29.71% |
| Jun 30, 2023 | 102.91% |
| Mar 31, 2023 | 66.82% |
| Dec 31, 2022 | 15.56% |
| Sep 30, 2022 | 74.21% |
| Jun 30, 2022 | 80.13% |
| Mar 31, 2022 | 78.04% |
| Dec 31, 2021 | 304.05% |
| Sep 30, 2021 | 32.22% |
| Jun 30, 2021 | -41.42% |